Piper Sandler, Nektar
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 and touched a low of $1.
GlobalData on MSN21h
Nektar Therapeutics to sell Alabama facility to AmpersandThe transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...
Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of ...
After Close of U.S.-Based Financial Markets Nektar Therapeutics will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback